key: cord-0624492-886iy9kz authors: Kim, QHwan; Ko, Joon-Hyuk; Kim, Sunghoon; Park, Nojun; Jhe, Wonho title: Bayesian neural network with pretrained protein embedding enhances prediction accuracy of drug-protein interaction date: 2020-12-15 journal: nan DOI: nan sha: 23c4bccb26ea05f13704deb743dc52a2454de94e doc_id: 624492 cord_uid: 886iy9kz The characterization of drug-protein interactions is crucial in the high-throughput screening for drug discovery. The deep learning-based approaches have attracted attention because they can predict drug-protein interactions without trial-and-error by humans. However, because data labeling requires significant resources, the available protein data size is relatively small, which consequently decreases model performance. Here we propose two methods to construct a deep learning framework that exhibits superior performance with a small labeled dataset. At first, we use transfer learning in encoding protein sequences with a pretrained model, which trains general sequence representations in an unsupervised manner. Second, we use a Bayesian neural network to make a robust model by estimating the data uncertainty. As a result, our model performs better than the previous baselines for predicting drug-protein interactions. We also show that the quantified uncertainty from the Bayesian inference is related to the confidence and can be used for screening DPI data points. machine learning-based methods 7-10 have emerged as candidate of fast DPI identification. Recently, deep neural networks (DNNs) have attracted attention because they outperform other machine learning-based methods in various tasks, such as computer vision 11 and natural language processing 12, 13 . In the usual DPI task, a protein is represented as a 1-dimensional long sequence of amino acid characters. Thus the deep learning models for natural language processing have been broadly used to obtain useful protein features from the sequences. Previous studies in this approach include using recurrent neural networks with long short-term memory (LSTM) 14 or gated recurrent unit (GRU) 15 layers for their ability to identify long-term dependencies in sequential data [16] [17] [18] . The other studies have used convolutional neural networks (CNN) [19] [20] [21] [22] [23] to extract hidden local patterns in sequences. Different representations of pretiens, such as 2-dimensional contact maps 24, 25 or 3-dimensional atom coordinates 26, 27 , in addition to 1-dimensional sequences, also have been used to increase model performance. Supervised training of high-capacity DNN models from scratch requires a large amount of labeled training data points. For example, Mahajan et al. 28 showed that the more labeled data is required to increase accuracy after training with 10 9 images. However, currently available DPI datasets usually contain thousands of labeled protein sequences, a small number compared to the > 195 M unrevealed interaction information in UniProtKB 29 . The lack of qualified labeled data points suppresses the usage of more elaborated deep learning architectures, which could potentially increase performance and reliability 30 . In particular, the scarcity of labeled data of biology and chemistry-related tasks has been suggested consistently 10, 31 although the labeling require expensive and time-consuming experiments. To overcome the difficulties of learning with limited data, several studies have proposed methods to increase the expressiveness of the deep learning model without additional endeavor to label generation. Of those, transfer learning uses a model that is initially pretrained with a large corpus of data of different task. This pretrained model is then transferred to the target tasks by adding classification layers and fine-tuning with the original small dataset. Transfer learning approaches have shown substantial performance improvement in computer vision 32 , 2/22 natural language processing 13 , and structure-property prediction of molecules 33, 34 . In cases where labeled data is expensive, such as in scientific problems, the pretrained model can be prepared in an unsupervised manner, using large but unlabeled datasets. Winter et al. 33 Here, we propose an end-to-end deep learning framework for highly accurate DPI prediction with transfer learning and BNN. We choose the pretrained model as a stacked transformer architecture, which is trained with 250 million unlabelled protein sequences in an unsupervised manner 39 . The drug is represented by the molecular graph and encoded through the graph interaction network layers. Estimation of the model performance using three public DPI datasets shows that the proposed model outperforms previous approaches. In addition, the estimated uncertainty, which is obtained from the sampling output of BNN, is decomposed into modelbased and data-based elements, which can be used to further virtual screening of data points. In summary, the main contributions of our work are as follows. 1. We propose the first approach to predict DPI with the Bayesian neural network framework and the pretrained protein sequence model; 2. our method demonstrates highly accurate prediction of three public DPI datasets; 3. the output of BNN can estimate the confidence of the data points. We evaluate our model and other baseline models on three public DPI datasets: the BindingDB dataset 16 , the Human dataset 6 , and the C. elegans dataset 6 . BindingDB is a public database of experimentally measured binding affinities between the small molecules and proteins 5 positive interactions between 1,434 unique drugs and 2,504 unique proteins. Also, we use an 80%/10%/10% training/validation/testing random split. In this study, the DPI is defined as a binary label, which represents the presence of an interaction. Figure 1 (a) shows schematic of proposed model. The input data is a pair of strings consisting of a protein sequence and drug SMILES strings. The input data passes embedding layers to be encoded as a pair of representation vectors. These protein and drug representation vectors are then concatenated and passed through fully-connected layers, resulting in a prediction for the existence of an interaction. In each cycle of training, this prediction is compared with the ground truth, and model parameters are tuned to decrease the difference between the two using the backpropagation algorithm. To implement BNNs, we apply dropout layers in every layer except the pretrained layer, the concatenation layer, and the final fully-connected layer. Detailed descriptions of the model are given below. A protein sequence is represented as a list of amino acids provided in the raw training data. Note that we do not use a set of gene ontology annotations that provides high-level information on protein functions. To extract protein-level embeddings, we use the pretrained models from Rives et al. 39 , which were trained with 250 million protein sequences in an unsupervised manner. Rives et al. used an attention-based transformer architecture 12 , and found that their model outperforms other recurrent network-based methods for predicting protein functionality. We select three models, Trans6, Trans12, and Trans34, which are pretrained with 6, 12, and 34 transformer layers, respectively. For each protein sequence of length L p , the pretrained models outputs an embedding matrix X p ∈ R L×d , where d = 768 for Trans6, Trans12 and d = 1, 280 for Trans34 model. From aminoacid level feature X p , we obtain the protein level feature x (0) p ∈ R d by averaging over the L amino acids features. With the protein-level embedding x (0) p , we use three 1-dimensional convolutional neural networks (1D-CNN) to smooth patterns in protein features. Note that the 1D-CNN gives slightly better performance than the fully-connected layers. The raw training data of drugs is in the SMILES (Simplified Molecular Input Line Entry System) format 40 . For each input SMILES string, we construct a corresponding molecular graph that contains connectivity and structure information of the compound. In the molecular graph, atoms and bonds are represented with vectors with structural features that characterize the surrounding chemical environment. The details of the attributes are shown in Supplmentary Table 1 The GraphNet first updates an edge between i-and j-th node as, where ⊕ is the concatenation operator, W where W (l) v is the weight matrix of node update, and b (l) v is the bias. After the update of node states is finalized, we obtain a graph feature (molecular feature) by gathering all the node and processed by, where N is the number of nodes in the molecular graph. We prepare the drug-protein feature vector x by concatenating x p and x d , In the classifier block, the feature vector x passes fully connected (FC) layers with ReLU activation to output final prediction value. The dimension of the last layer is 2, corresponding to the one-hot encoding of the binary classification labels. for a new input x * and a new output y * . The direct computation of Eq. A variational inference approximating a posterior a variational distribution q θ (w) provides a variational predictive distribution of a new output y * given a new input x * as whereŷ(w) * t is a output of input x * t with a given w. In BNN, the integration in Eq. (6) is replaced with a predictive mean of T times of MC sampling, which is estimated bŷ In estimating its predictive variance, we decompose the source of uncertainty into aleatoric The predictive variance is estimated bŷ We implement the proposed model with Pytorch 1. The training objective is to minimize the loss function L, given by the sum of the crossentropy loss and the regularization as follows where w is the set of model parameters, N is the number of interaction labels, and λ is an L2 regularization hyperparameter. To implement MC-dropout sampling, we turn on dropout layers in estimating test dataset with T = 30 samplings. The mean performance and the decomposed uncertainties of the output are calculated with Eq. (7) and Eq. (8), respectively. The main performance metric was chosen to be the area under the receiver operating curve (ROC-AUC). We also report some additional performance metrics -accuracy for the BindingDB dataset, and precision and recall for the Human and C. elegans dataset. To train DPI datasets, we prepare six models, Trans6, Trans12, Trans34, Trans6+Drop, Trans12+Drop, and Trans34+Drop. The latter three models use the pretrained protein model and implement the BNN architecture with MC-Dropout ( Fig. 1 (a) ), while the former three models only use the pretrained model. The numbers 6, 12, and 34 correspond to the number of transformer layers in the pretrained model. With the BindingDB dataset, we compare our model against three baselines: Tiresias, DBN, and E2E. Tiresias uses similarity measures of drug and protein pairs 7 . DBN uses stacked restricted Boltzmann machines with the inputs as extended connectivity fingerprints 9 . E2E uses graph convolutional networks and LSTM to process drug-protein pair information with Gene Ontology annotations 16 . Following suggestions from previous works, we further split the test dataset into four sub-test sets that the model can be learned and applied to predict the label between a drug and protein target. The binary interaction test data is divided by "seen" and "unseen" whether the protein and drug are observed in the training dataset. Our results show that models with both transfer learning and BNN (Trans6+Drop, Trans12+Drop, Trans34+Drop) outperform other baseline models when evaluated with three public DPI datasets. We note that only the pretrained protein sequence can train models (Trans6, Trans12, Trans34) competitive with the baselines, but additional Bayesian frameworks further increase performance. It suggests that the role of BNN, training robust model, is the key figure of performance enhancement as well as the expression capacity obtained from the pretrained model. An additional point to mention is that the most complex model, Trans34+Drop, does not always give the best results. This is in agreement with the literature, where it was found that the prediction accuracy is not strictly proportional to the sequence model complexity 39 . Therefore, when using transfer learning, we recommend preparing several different pretrained models and comparing their results before making the final choice. In this section, we test the robustness of the Bayesian models by varying the quality of the protein data. The robustness is estimated by tracking the degradation of the model performance as more and more external noise is added to the dataset. The type of noise for the experiment is chosen to be the Gaussian noise N (0, σ 2 ), where 0 is the mean and σ is the standard deviation of the distribution. We first test whether the uncertainties obtained from the proposed BNN model are correctly estimated. This is accomplished by reducing the training set sizes and observing the resulting uncertainty changes. When dataset size is decreased, aleatoric uncertainty, which is related to the inherent noise of the data, should stay constant, whereas the model error-related epistemic noise should increase to a lack of sufficient training data. Note that there is no consistent trend regarding which uncertainty is more important, and two uncertainties should be treated equally to achieve an accurate estimation. In this study, we present a novel Bayesian deep learning framework with a pretrained protein se- The GraphNet performs message passing on the molecular graph, recursively updating graph edges e (l) and nodes v (l) . Performance comparison of proposed models, similarity-based approach (Tiresias), stacked restricted Boltzmann layers (DBN), and graph convolutional networks -long short-term memory-based approach (E2E). For each model, two metrics are reported: area under receiver operating characteristic curve (ROC-AUC) and accuracy. The binary interaction test data is divided by "seen" and "unseen" whether the protein and drug are observed in the training dataset. The accuracy score of Tiresias is not seen in the bottom graphs because they are lower than the lower bound of y-axis. (a) (b) (c) Table 1 . ROC-AUC, Precision, and Recall scores of human and C. elegans dataset with proposed models, k-nearest neighbor (k-NN), random forest (RF), L2 logistic (L2), support vector machine (SVM), and graph neural network (GNN) proposed by Tsubaki et al. 22 . The best score of proposed models is emphasized in bold. The italicized scores correspond to the best scores for the baseline models. Relating drug-protein interaction network with drug side effects Elucidating mechanisms of drug-induced toxicity Drug repurposing: progress, challenges and recommendations Review of drug repositioning approached and resources BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities Improving compound-protein interaction prediction by building up highly credible negative samples Predicting drug-drug interactions through large-scale similarity-based link prediction. Int. Semantic Web Conf SimBoost: a read-across approach for predicting drug-target binding affinities using gradient boosting machines Deep-learning-based drug-target interaction prediction Applications of machine learning in drug discovery and development Deep residual learning for image recognition Attention is all you need Pre-training of deep bidirectional transformers for language understanding Long short-term memory On the properties of neural machine translation: Encoder-decoder approaches Interpretable drug target prediction using deep neural representation DeepAffinity: interpretable deep learning of compund-protein affinity through unified recurrent and convolutional neural networks A deep learning-based method for drug-target interaction prediction based on long short-term memory neural network DeepDTA: deep drug-target binding affinity prediction DeepConv-DTI: Prediction of drug-target interactions via deep All authors contributed to construct concept and initialize the project. Q.K and W.J made the program. All authors participated in the discussion of the results. Q.K and W.J wrote the manuscript.All authors reviewed the manuscript. The authors declare no competing interests.